CN106916132A - A kind of synthetic method of medicine intermediate coumarin derivatives - Google Patents

A kind of synthetic method of medicine intermediate coumarin derivatives Download PDF

Info

Publication number
CN106916132A
CN106916132A CN201710215222.9A CN201710215222A CN106916132A CN 106916132 A CN106916132 A CN 106916132A CN 201710215222 A CN201710215222 A CN 201710215222A CN 106916132 A CN106916132 A CN 106916132A
Authority
CN
China
Prior art keywords
compound
formula
catalyst
synthetic method
auxiliary agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201710215222.9A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201710215222.9A priority Critical patent/CN106916132A/en
Publication of CN106916132A publication Critical patent/CN106916132A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/14—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 6 and unsubstituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B01J31/2282—Unsaturated compounds used as ligands
    • B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/30—Addition reactions at carbon centres, i.e. to either C-C or C-X multiple bonds
    • B01J2231/32—Addition reactions to C=C or C-C triple bonds
    • B01J2231/324—Cyclisations via conversion of C-C multiple to single or less multiple bonds, e.g. cycloadditions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/821—Ruthenium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

The present invention relates to a kind of synthetic method of medicine intermediate coumarin derivatives shown in lower formula (III), methods described includes：Under nitrogen atmosphere, to formula (I) compound, lower formula (II) compound, catalyst, accelerator and auxiliary agent under being added in organic solvent, then in stirring reaction 58 hours at 70 90 DEG C, then it is post-treated, obtain the formula (III) compoundWherein, R1、R2It is each independently selected from H, C1‑C6Alkyl or halogen；R 3、R4It is each independently selected from C1‑C6Alkyl, phenyl unsubstituted or with substituted base, the substitution base are C1 C6 alkoxy or halogens.The method passes through the comprehensive selection of catalyst, accelerator, auxiliary agent and organic solvent and cooperates with, and purpose product is obtained such that it is able to high yield, and in organic synthesis field, especially medicine intermediate synthesis field has extensive industrial application value and productive potentialities.

Description

A kind of synthetic method of medicine intermediate coumarin derivatives
Technical field
The present invention relates to a kind of synthetic method of fused ring compound, relate more particularly to a kind of medicine intermediate Coumarins The synthetic method of derivative, belongs to organic chemical synthesis field especially medicine intermediate synthesis field.
Background technology
In organic chemistry and medicine intermediate synthesis technical field, tonka bean camphor structure is many natural products and medicine The basic structure fragment of compound, it assigns these compounds extensive bioactivity.Additionally, coumarin derivatives can also be used for Prepare among luminous organic material or molecular device.
Just because of the so important effect of perfume bucket chlorins compound and application potential, therefore, research and develop Coumarins chemical combination The novel method for synthesizing of thing is very significant thing.
Traditional Coumarins synthetic method is reacted for Pechmann, also can be using the condensation reaction of strong acid or strong base catalyst Method.Additionally, the synthetic method about metal catalytic also has been reported that more in recent years, it is illustratively as follows：
(" the New Method for Preparation of Coumarins and Quinolinones such as Jia Chengguo via Pd-Catalyzed Intramolecular Hydroarylation of C-C TripleBonds”, J.Org, Chem., 2000,65,7516-7522) report a kind of inner molecular reaction of palladium chtalyst and prepare the method for cumarin its reaction equation It is as follows：
(" the Atom Economy. Palladium-Catalyzed Formation of such as Barry M. Trost Coumarins by Addition of Phenols and Alkynoates via a Net C-H Insertion”, J.Am. Chem. Soc., 2003,125,4518-4526) report it is a kind of by phenolic compound and alkynyl ester type compound Palladium chtalyst synthetic reaction, its reaction equation is as follows：
(" Palladium (II)-Catalyzed Direct Carboxylation of Alkenyl such as Kota Sasano C-H Bonds with CO2 ", J.Am.Chem. Soc., 2013,135,10954-10957) report a kind of carbon dioxide The synthetic reaction of the palladium chtalyst of participation, its reaction equation is as follows：
In order to expand new reaction type, the present inventor on the basis of existing technology, is studied and purport by a large amount of scientific experiments A kind of method that cyclization prepares coumarin derivatives is being provided, it uses multiple elements design reaction system to promote significantly and urges Change the smooth implementation of reaction, and achieve significant technique effect, show extremely to be widely applied prospect.
The content of the invention
In order to seek the novel method for synthesizing of coumarin derivatives, present inventor has performed in-depth study and exploration, After enough creative works have been paid, so as to complete the present invention.
Specifically, technical scheme and content are related to coumarin derivatives shown in a kind of lower formula (III) Synthetic method, methods described includes：Under nitrogen atmosphere, to formula (I) compound, lower formula (II) chemical combination under being added in organic solvent Thing, catalyst, accelerator and auxiliary agent, it is then post-treated then in stirring reaction 5-8 hours at 70-90 DEG C, obtain the formula (III) compound,
Wherein, R1、R2It is each independently selected from H, C1-C6Alkyl or halogen；
R3、R4It is each independently selected from C1-C6Alkyl, phenyl unsubstituted or with substituted base, the substitution base are C1-C6Alcoxyl Base or halogen.
In the synthetic method of the invention, the C1-C6The implication of alkyl refers to the 1-6 straight chain of carbon atom Or branched alkyl, for example can be in non-limiting manner methyl, ethyl, n-propyl, isopropyl, normal-butyl, sec-butyl, isobutyl group, uncle Butyl, n-pentyl, isopentyl or n-hexyl etc..
In the synthetic method of the invention, the C1-C6Alkoxy refers to " C defined above1-C6Alkyl " is former with O Group after son is connected.
In the synthetic method of the invention, the implication of the halogen refers to halogen, for example can be non-exclusively F, Cl, Br or I.
In the synthetic method of the invention, the catalyst is ruthenium compound and Bu2(dibutyl iodine tin is hydrogenated SnIH Thing) mixture, wherein ruthenium compound and Bu2The mol ratio of SnIH is 1:3.
Wherein, the ruthenium compound is ruthenocene, triphenylphosphine ruthenic chloride, the ruthenium of four carbonyl dichloride two or hydroxy chloride ruthenium In any one, most preferably triphenylphosphine ruthenic chloride.
In the synthetic method of the invention, the accelerator is organocopper compound, and it is selected from copper acetate
(Cu(OAc)2), copper trifluoromethanesulfcomposite (Cu (OTf)2), acetylacetone copper (Cu (acac)2) or trifluoroacetic acid copper (Cu (TFA)2Any one of), most preferably acetylacetone copper (Cu (acac)2)。
In the synthetic method of the invention, the auxiliary agent is 1- ethyl-3-methylimidazoles acetate or 1- ethyls -3- Any one in methylimidazole trifluoroacetate, most preferably 1- ethyl-3-methylimidazoles trifluoroacetate.
In the synthetic method of the invention, the organic solvent is Isosorbide-5-Nitrae-dioxane and DMSO (dimethyl sulfoxide (DMSO)) Mixture；Wherein, Isosorbide-5-Nitrae-dioxane and the volume ratio of DMSO are 1:2-3, for example, can be 1:2、1:2.5 or 1:3.
In the synthetic method of the invention, the consumption of the organic solvent is not particularly limited, this area skill Art personnel may be selected suitable consumption, for example, cause that reacting balance is carried out, or post-process the amount for being easy to carry out, and this belongs to ability The conventional technical means in domain, this is no longer going to repeat them.
In the synthetic method of the invention, formula (I) compound is 1 with the mol ratio of formula (II) compound: 1.4-2, in non-limiting manner for example can 1:1.4、1:1.6、1:1.8 or 1:2.
In the synthetic method of the invention, formula (I) compound is 1 with the mol ratio of catalyst:0.08- 0.14, i.e., mole dosage and the ruthenium compound of the composition catalyst and the total moles of Bu2SnIH of described formula (I) compound are used The ratio of amount is 1:0.08-0.14, for example, can be 1:0.08、1:0.1、1:0.12 or 1:0.14.
In the synthetic method of the invention, formula (I) compound is 1 with the mol ratio of accelerator:0.2-0.3, For example can be 1:0.2、1:0.25 or 1:0.3.
In the synthetic method of the invention, formula (I) compound is 1 with the mol ratio of auxiliary agent:0.1-0.15, example Such as can be 1:0.1、1:0.12、1:0.14 or 1:0.15.
In the synthetic method of the invention, the post processing for terminating is reacted specific as follows：It is after reaction terminates, reaction is mixed Compound is filtered while hot, and filtrate naturally cools to room temperature, is added deionized water and is fully vibrated, and is added chloroform and is fully extracted 2-3 It is secondary, merge organic phase, it is concentrated under reduced pressure, gained residue is crossed into silica gel flash column chromatography, it is 1 with volume ratio:2 ethyl acetate and The mixed solvent of acetone as eluent, so as to obtain the formula (III) compound.
In sum, the invention provides a kind of synthetic method of coumarin derivatives, the method is by catalyst, rush Enter the comprehensive selection of agent, auxiliary agent and organic solvent and cooperate with, purpose product is obtained such that it is able to high yield, in organic synthesis field Especially medicine intermediate synthesis field has extensive industrial application value and productive potentialities.
Specific embodiment
Below by specific embodiment, the present invention is described in detail, but the purposes of these exemplary embodiments and Purpose is only used for enumerating the present invention, not constitutes any type of any restriction to real protection scope of the invention, more non-to incite somebody to action Protection scope of the present invention is confined to this.
Embodiment 1
At room temperature, under nitrogen atmosphere, (it is volume ratio 1 to appropriate organic solvent:2 1,4- dioxane and the mixing of DMSO Thing) in, it (is 2mmol triphens to add formula (I) compound on 100mmol, the upper formula (II) compounds of 140mmol, 8mmol catalyst The Bu of base phosphine ruthenic chloride and 6mmol2The mixture of SnIH), 20mmol accelerant Cs u (acac)2With 10mmol auxiliary agent 1- ethyls -3- Methylimidazole trifluoroacetate；Then heat to 70 DEG C and at such a temperature stirring reaction 8 hours；
After reaction terminates, reactant mixture is filtered while hot, filtrate naturally cools to room temperature, adds deionized water and fully shakes Swing, add chloroform and fully extract 2-3 times, merge organic phase, be concentrated under reduced pressure, gained residue is crossed into silica gel flash column chromatography, It is 1 with volume ratio:2 ethyl acetate and the mixed solvent of acetone, so as to obtain upper formula (III) compound, are produced as eluent Rate is 97.6%.
1HNMR(CDCl3,400MHz):δ2.29(s,3H),6.99(s,1H),7.08-7.16(m,4H),7.18-7.22 (m,3H),7.28-7.37(m,5H)。
Embodiment 2
At room temperature, under nitrogen atmosphere, (it is volume ratio 1 to appropriate organic solvent:2.5 1,4- dioxane is mixed with DMSO Compound) in, formula (I) compound, the upper formula (II) compounds of 170mmol, 11mmol catalyst (are on addition 100mmol The Bu of 2.75mmol triphenylphosphines ruthenic chloride and 8.25mmol2The mixture of SnIH), 25mmol accelerant Cs u (acac)2With 12mmol auxiliary agent 1- ethyl-3-methylimidazole trifluoroacetates；Then heat to 80 DEG C and stirring reaction 6 is small at such a temperature When；
After reaction terminates, reactant mixture is filtered while hot, filtrate naturally cools to room temperature, adds deionized water and fully shakes Swing, add chloroform and fully extract 2-3 times, merge organic phase, be concentrated under reduced pressure, gained residue is crossed into silica gel flash column chromatography, It is 1 with volume ratio:2 ethyl acetate and the mixed solvent of acetone, so as to obtain upper formula (III) compound, are produced as eluent Rate is 97.3%.
1HNMR(CDCl3,400MHz):δ6.88-6.96(m,2H),7.02-7.13(m,6H),7.18-7.24(m,2H), 7.45 (d, J=8.4Hz, 1H), 7.56-7.59 (m, 1H).
Embodiment 3
At room temperature, under nitrogen atmosphere, (it is volume ratio 1 to appropriate organic solvent:3 1,4- dioxane and the mixing of DMSO Thing) in, it (is 3.5mmol tri- to add formula (I) compound on 100mmol, the upper formula (II) compounds of 200mmol, 14mmol catalyst The Bu of Phenylphosphine ruthenic chloride and 10.5mmol2The mixture of SnIH), 30mmol accelerant Cs u (acac)2With 15mmol auxiliary agent 1- second Base -3- methylimidazole trifluoroacetates；Then heat to 90 DEG C and at such a temperature stirring reaction 5 hours；
After reaction terminates, reactant mixture is filtered while hot, filtrate naturally cools to room temperature, adds deionized water and fully shakes Swing, add chloroform and fully extract 2-3 times, merge organic phase, be concentrated under reduced pressure, gained residue is crossed into silica gel flash column chromatography, It is 1 with volume ratio:2 ethyl acetate and the mixed solvent of acetone, so as to obtain upper formula (III) compound, are produced as eluent Rate is 97.2%.
1HNMR(CDCl3,400MHz):δ3.77(s,3H),3.82(s,3H),6.73-6.76(m,2H),6.83-6.89 (m,2H), 7.04-7.08(m,4H),7.17-7.23(m,1H),7.27-7.31(m,1H),7.39-7.45(m,1H),7.48- 7.53 (m,1H)。
Embodiment 4
At room temperature, under nitrogen atmosphere, (it is volume ratio 1 to appropriate organic solvent:2.5 1,4- dioxane is mixed with DMSO Compound) in, it (is 2.5mmol to add formula (I) compound on 100mmol, the upper formula (II) compounds of 160mmol, 10mmol catalyst The Bu of triphenylphosphine ruthenic chloride and 7.5mmol2The mixture of SnIH), 25mmol accelerant Cs u (acac)2With 12mmol auxiliary agents 1- Ethyl-3-methylimidazole trifluoroacetate；Then heat to 75 DEG C and at such a temperature stirring reaction 6 hours；
After reaction terminates, reactant mixture is filtered while hot, filtrate naturally cools to room temperature, adds deionized water and fully shakes Swing, add chloroform and fully extract 2-3 times, merge organic phase, be concentrated under reduced pressure, gained residue is crossed into silica gel flash column chromatography, It is 1 with volume ratio:2 ethyl acetate and the mixed solvent of acetone as eluent, so as to obtain upper formula (III) compound (" n- Bu " is normal-butyl), yield is 97.4%.
1HNMR(CDCl3,400MHz):δ 0.98 (t, J=7.2Hz, 3H), 1.02 (t, J=7.2Hz, 3H), 1.44-1.62 (m, 8H), 2.65 (t, J=8.0Hz, 2H), 2.83 (t, J=8.0Hz, 2H), 7.25-7.33 (m, 2H), 7.44-7.48 (m, 1H), 7.59 (dd, J1=8.0Hz, J2=1.2Hz, 1H).
Embodiment 5-24
Embodiment 5-8：In addition to the triphenylphosphine ruthenic chloride in catalyst is replaced with into ruthenocene, other operations are constant, so that Embodiment 1-4 is repeated, embodiment 5-8 is obtained.
Embodiment 9-12：In addition to the triphenylphosphine ruthenic chloride in catalyst is replaced with into the ruthenium of four carbonyl dichloride two, other Operation is constant, so as to embodiment 1-4 is repeated, obtains embodiment 9-12.
Embodiment 13-16：In addition to the triphenylphosphine ruthenic chloride in catalyst is replaced with into hydroxy chloride ruthenium, other operations are equal It is constant, so as to embodiment 1-4 is repeated, obtain embodiment 13-16.
Embodiment 17-20：Except catalyst is replaced with into the one-component three that consumption is the original total consumption sum of two kinds of components Outside Phenylphosphine ruthenic chloride, other operations are constant, so as to embodiment 1-4 is repeated, obtain embodiment 17-20.
Embodiment 21-24：Except catalyst is replaced with into the one-component that consumption is the original total consumption sum of two kinds of components Outside Bu2SnIH, other operations are constant, so as to embodiment 1-4 is repeated, obtains embodiment and obtain embodiment 21-24.
Result see the table below 1.
Table 1
" -- " represents do not exist.
As can be seen here, in ruthenium compound, triphenylphosphine ruthenic chloride has best effect.It can also be seen that only same When use triphenylphosphine ruthenic chloride and Bu2During the composite catalyst of SnIH, excellent technique effect of the invention could be obtained；And work as Triphenylphosphine ruthenic chloride or Bu is used alone2During SnIH, will all cause yield to be significantly reduced, especially be single use Bu2During SnIH, yield is drastically reduced.Thus triphenylphosphine ruthenic chloride and Bu are demonstrated2The collaboration of uniqueness can be played between SnIH Catalytic effect.
Embodiment 25-40
Embodiment 25-28：Except accelerator is replaced with into Cu (OAc)2Outward, other operations are constant, so as to implementation is repeated Example 1-4, obtains embodiment 25-28.
Embodiment 29-32：Except accelerator is replaced with into Cu (OTf)2Outward, other operations are constant, so as to be repeated Embodiment 1-4, obtains embodiment 29-32.
Embodiment 33-36：Except accelerator is replaced with into Cu (TFA)2Outward, other operations are constant, so as to be repeated Embodiment 1-4, obtains embodiment 33-36.
Embodiment 37-40：In addition to accelerator is dispensed, other operations are constant, so as to embodiment 1-4 is repeated, Obtain embodiment 37-40.
Result see the table below 2.
Table 2
" -- " represents do not exist.
As can be seen here, acetylacetone copper (Cu (acac)2) there is best facilitation effect, other copper compounds cause to produce Thing decrease to some degree, and when auxiliary agent is not used, yield reduction becomes apparent, this demonstrate that acetylacetone copper (Cu (acac)2) there is unexpected promotion synergy.
Embodiment 41-48
Embodiment 41-44：In addition to auxiliary agent to be replaced with 1- ethyl-3-methylimidazole acetates, other operations are constant, so that weight A 1-4 is carried out again, obtains embodiment 41-44.
Embodiment 45-48：In addition to auxiliary agent is dispensed, other operations are constant, so as to embodiment 1-4 is repeated, obtain To embodiment 45-48.
Result see the table below 3.
Table 3
" -- " represents do not exist.
As can be seen here, the presence of auxiliary agent can significantly improve products collection efficiency, and 1- ethyl-3-methylimidazole trifluoroacetates With best auxiliaring effect.
Embodiment 49-56
Embodiment 49-52：In addition to organic solvent to be replaced with one-component Isosorbide-5-Nitrae-dioxane, other operations are constant, so that Embodiment 1-4 is repeated, embodiment 49-52 is obtained.
Embodiment 53-56：In addition to organic solvent is replaced with into one-component DMSO, other operations are constant, so as to repeat A 1-4 is carried out, embodiment 53-56 is obtained.
Result see the table below 4.
Table 4
As can be seen here, when using single solvent, yield decrease to some degree, this proves only to use Isosorbide-5-Nitrae-dioxane With the bi-component organic solvent of DMSO, excellent effect of the invention could be obtained.
In sum, the invention provides a kind of synthetic method of coumarin derivatives, the method is by catalyst, rush Enter the comprehensive selection of agent, auxiliary agent and organic solvent and cooperate with, purpose product is obtained such that it is able to high yield, in organic synthesis field Especially medicine intermediate synthesis field has extensive industrial application value and productive potentialities.
It should be appreciated that the purposes of these embodiments is merely to illustrate the present invention and is not intended to limit protection model of the invention Enclose.Additionally, it will also be appreciated that after technology contents of the invention have been read, those skilled in the art can make each to the present invention Plant and change, change and/or modification, all these equivalent form of value equally falls within the guarantor that the application appended claims are limited Within the scope of shield.

Claims (1)

1. a kind of synthetic method of coumarin derivatives shown in lower formula (III), methods described includes：Under nitrogen atmosphere, to Lower formula (I) compound, lower formula (II) compound, catalyst, accelerator and auxiliary agent are added in organic solvent, then in 70-90 DEG C Lower stirring reaction 5-8 hours, after reaction terminates, reactant mixture is filtered while hot, and filtrate naturally cools to room temperature, adds Ionized water is fully vibrated, and adds chloroform and fully extracts 2-3 times, merges organic phase, is concentrated under reduced pressure, and gained residue is crossed into silica gel Flash column chromatography, is 1 with volume ratio:2 ethyl acetate and the mixed solvent of acetone obtain the formula (III) as eluent Compound,
Wherein, R1、R2It is each independently selected from H, C1-C6Alkyl or halogen；
R3、R4It is each independently selected from C1-C6Alkyl, phenyl unsubstituted or with substituted base, the substitution base are C1-C6Alcoxyl Base or halogen；
The catalyst is ruthenium compound and Bu2The mixture of SnIH, wherein ruthenium compound and Bu2The mol ratio of SnIH is 1:3；
The ruthenium compound is triphenylphosphine ruthenic chloride；
The accelerator is acetylacetone copper；
The auxiliary agent is 1- ethyl-3-methylimidazole trifluoroacetates；
The organic solvent is the mixture of 1,4- dioxane and DMSO (dimethyl sulfoxide (DMSO))；Wherein, Isosorbide-5-Nitrae-dioxane with The volume ratio of DMSO is 1:2-3.
CN201710215222.9A 2015-08-20 2015-08-20 A kind of synthetic method of medicine intermediate coumarin derivatives Withdrawn CN106916132A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710215222.9A CN106916132A (en) 2015-08-20 2015-08-20 A kind of synthetic method of medicine intermediate coumarin derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510514922.9A CN105085458B (en) 2015-08-20 2015-08-20 A kind of synthetic method of coumarin derivatives
CN201710215222.9A CN106916132A (en) 2015-08-20 2015-08-20 A kind of synthetic method of medicine intermediate coumarin derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201510514922.9A Division CN105085458B (en) 2015-08-20 2015-08-20 A kind of synthetic method of coumarin derivatives

Publications (1)

Publication Number Publication Date
CN106916132A true CN106916132A (en) 2017-07-04

Family

ID=54566877

Family Applications (7)

Application Number Title Priority Date Filing Date
CN201710215214.4A Withdrawn CN106977481A (en) 2015-08-20 2015-08-20 A kind of synthetic method of coumarin derivatives
CN201510514922.9A Expired - Fee Related CN105085458B (en) 2015-08-20 2015-08-20 A kind of synthetic method of coumarin derivatives
CN201710215217.8A Withdrawn CN106957292A (en) 2015-08-20 2015-08-20 The synthetic method of medicine intermediate coumarin derivatives
CN201710215226.7A Withdrawn CN106957294A (en) 2015-08-20 2015-08-20 The synthetic method of medicine intermediate coumarin derivatives
CN201710215223.3A Withdrawn CN106957293A (en) 2015-08-20 2015-08-20 The synthetic method of coumarin derivatives
CN201710215222.9A Withdrawn CN106916132A (en) 2015-08-20 2015-08-20 A kind of synthetic method of medicine intermediate coumarin derivatives
CN201710215202.1A Withdrawn CN106946826A (en) 2015-08-20 2015-08-20 A kind of synthetic method of medicine intermediate coumarin derivatives

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CN201710215214.4A Withdrawn CN106977481A (en) 2015-08-20 2015-08-20 A kind of synthetic method of coumarin derivatives
CN201510514922.9A Expired - Fee Related CN105085458B (en) 2015-08-20 2015-08-20 A kind of synthetic method of coumarin derivatives
CN201710215217.8A Withdrawn CN106957292A (en) 2015-08-20 2015-08-20 The synthetic method of medicine intermediate coumarin derivatives
CN201710215226.7A Withdrawn CN106957294A (en) 2015-08-20 2015-08-20 The synthetic method of medicine intermediate coumarin derivatives
CN201710215223.3A Withdrawn CN106957293A (en) 2015-08-20 2015-08-20 The synthetic method of coumarin derivatives

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710215202.1A Withdrawn CN106946826A (en) 2015-08-20 2015-08-20 A kind of synthetic method of medicine intermediate coumarin derivatives

Country Status (1)

Country Link
CN (7) CN106977481A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106432049A (en) * 2016-09-27 2017-02-22 李纪焕 Benzo-succinimide compound synthesis method
CN106432050A (en) * 2016-09-27 2017-02-22 李纪焕 Improved synthesis method for imine compound
CN109369597B (en) * 2018-12-28 2022-11-29 陕西师范大学 Synthetic method of isocoumarin compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100494128C (en) * 2006-12-28 2009-06-03 上海交通大学 Method for synthesizing styrene derivative from active arene and alkyne catalyzed by iron
WO2013049567A1 (en) * 2011-09-29 2013-04-04 The Broad Institute, Inc. Compounds for the treatment of mycobacterial infections
CN103408554B (en) * 2013-07-31 2015-07-08 西安交通大学 Hypertensive activity reducing pyrrole coumarins compound and preparation method thereof

Also Published As

Publication number Publication date
CN106957294A (en) 2017-07-18
CN106957293A (en) 2017-07-18
CN106957292A (en) 2017-07-18
CN105085458A (en) 2015-11-25
CN106977481A (en) 2017-07-25
CN105085458B (en) 2017-04-05
CN106946826A (en) 2017-07-14

Similar Documents

Publication Publication Date Title
CN105085458B (en) A kind of synthetic method of coumarin derivatives
CN109180625A (en) A kind of preparation method of seleno flavone compound
CN105461624B (en) A kind of method that sulfosalicylic acid collaboration cyclopentadienyl titanium dichloride water mutually efficiently prepares quinoline
CN105175373B (en) Synthetic method of aryl ketone coumarin derivative
CN110041220B (en) Symmetrical imide compound and synthetic method thereof
CN105801338B (en) A method of synthesizing medicine intermediate phenanthrene class compound using palladium acetylacetonate
CN104961734B (en) A kind of synthetic method of medicine intermediate heterocycle-substituted pyridine nitrogen oxides
CN105384710B (en) A kind of synthetic method of pharmaceutical intermediate furfuran compound
CN105001135A (en) Chemical synthetic method for raphanin
CN106045916B (en) A kind of synthetic method of imidazolone compounds
CN102584512A (en) Method for synthesizing benzofuran derivatives in one pot process
CN105152828B (en) A kind of synthetic method of alkynyl assimilation compound
CN107098835A (en) A kind of synthetic method of medicine intermediate sulfide compound
CN110963971A (en) Preparation method for synthesizing rosuvastatin calcium intermediate
CN105061391B (en) A kind of synthetic method of sweet-smelling alkynyl substituted heterocycle ketone compounds
CN113292534B (en) Preparation method of bilastine key intermediate
CN107459530A (en) A kind of 1,3 isoquinolin derovatives of novel silicon base substitution and preparation method thereof
CN105294600B (en) A kind of synthetic method of medicine intermediate diketone aminated compounds
CN105153152B (en) A kind of synthetic method of imidazoles fused ring compound
CN105801342B (en) A kind of method that medicine intermediate phenanthrene compound is synthesized under diisopropylamine environment
CN104788273B (en) A kind of synthetic method of medicine intermediate ketone ester compounds
CN105753620B (en) A method of synthesizing medicine intermediate phenanthrene compound using copper trifluoromethanesulfcomposite
CN105753619B (en) A method of synthesizing medicine intermediate phenanthrene compound using copper acetate
CN104693001B (en) A kind of synthetic method of pharmaceutical intermediate condensed ring compounds
CN101787024B (en) Quinoline

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20170704

WW01 Invention patent application withdrawn after publication
DD01 Delivery of document by public notice

Addressee: Qian Xiaoying

Document name: Notification of Approving Refund

DD01 Delivery of document by public notice